OSE-2101 is under clinical development by OSE Immunotherapeutics and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Squamous Non-Small Cell Lung Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how OSE-2101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OSE-2101 overview
OSE-2101 (EP-2101, Texopi, Tedopi) is under development for the treatment of non-small cell lung cancer, non-mucinous epithelial ovarian cancer and advanced or metastatic pancreatic ductal adenocarcinoma. It is administered subcutaneously. It acts by targeting carcinoembryonic antigen-related cell adhesion molecule 5, HER2, MAGE 2, MAGE3. It is based upon Memopi technology.
It was also under development for the treatment of colon cancer, triple negative breast cancer, mesothelioma, brain metastasis.
OSE Immunotherapeutics overview
OSE Immunotherapeutics (OSE) is a clinical-stage biotechnology company that primarily focuses on the development and partnership of therapies in the fields of immuno-oncology and immuno-inflammation. The company’s main activities include proprietary research platforms to develop first-in-class clinical assets that aim to control the immune system. Its product pipeline includes therapies such as Tedopi, OSE-127, OSE-279, FR104/VEL-101, and BI 770371, that are designed for various indications including solid tumors, chronic inflammation, and kidney transplant. The company’s products are targeted towards the healthcare industry, specifically in the treatment of diseases like non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and ulcerative colitis (UC). OSE is headquartered in Nantes, Pays-de-la-Loire, France.
For a complete picture of OSE-2101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
